The highly contagious Omicron subvariant BA.2 is now the dominant COVID-19 variant in the United States, the Centers for Disease Control and Prevention (CDC) estimated on March 29.
According to CDC data, BA.2 is projected to account for nearly 55% of new COVID-19 cases in the U.S., as of March 26.
BA.2 has not caused a significant surge in other countries and scientists believe it does not cause more severe disease
However, BA.2 has raised concern in Northeast communities, which has reported an increase in cases in recent weeks.
The CDC estimated that BA.2 accounted for over 70% of new cases in the New York-New Jersey region.
“This small increase in cases in the Northeast is something that we are watching very closely as we look for any indication of an increase in severe disease from COVID-19 and track whether this might represent an increase in the strain that’s being put on hospitals,” Dr. John Brooks from the CDC told an event hosted by Ethnic Media Services on March 25.
The presence of BA.2 has forced authorities to stop using a monoclonal antibody drug, which is a key COVID-19 treatment, because it is not effective against the subvariant.
© Fourth Estate
® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.